Tirzepatide linked to significant weight loss, impressive diabetes prevention after 3 years Tirzepatide is associated with significant weight loss and a reduced risk of type 2 diabetes among obese patients who present with prediabetes, according to a new three-year analysis published in the New England Journal of Medicine .[1] The findings, based on updated data from the randomized SURMOUNT-1 trial, were originally presented at the ObesityWeek 2024 conference in early November
Authors contributions GAA, JRI, and RGG participated in compiling data and elaborating the manuscript
On the compounding front, that window has largely closed
(2008) Exercise-induced oxidative stress: cellular mechanisms and impact on muscle force production
Using smaller plates, measuring portions, and eating slowly can help you recognise satiety cues and avoid overeating
Having trouble standing, walking, or lifting is not normal and should not happen during a simple adjustment
